Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
American Renal Associates Holdings, Inc. (ARA)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | S-1/A |
| Revenues | 822.5 | 805.8 | 729.0 | 756.3 | 657.5 | 563.6 | 495.9 |
| Revenue growth | 2.1% | 10.5% | -3.6% | 15.0% | 16.7% | 13.6% | |
| Cost of goods sold | 636.0 | 608.7 | 498.4 | 452.4 | 390.9 | 329.8 | 0.0 |
| Gross profit | 186.5 | 197.1 | 230.7 | 303.9 | 266.6 | 233.7 | 495.9 |
| Gross margin | 22.7% | 24.5% | 31.6% | 40.2% | 40.5% | 41.5% | 100.0% |
| Selling, general and administrative [+] | 91.1 | 102.0 | 102.8 | 129.9 | 79.3 | 63.0 | 72.6 |
| General and administrative [+] | 91.1 | 102.0 | 102.8 | 129.9 | 79.3 | 63.0 | 72.6 |
| General and administrative expenses | 91.1 | 101.1 | 102.1 | 127.6 | 77.3 | 63.0 | 72.6 |
| Professional fees | | 0.9 | 0.7 | 2.2 | 2.1 | | |
| Other operating expenses | | -2.3 | | 6.6 | 4.5 | 2.8 | 288.9 |
| Adjusted EBITDA | 100.2 | 103.1 | 143.7 | 207.7 | 184.1 | 168.9 | 154.8 |
| Adjusted EBITDA margin | 12.2% | 12.8% | 19.7% | 27.5% | 28.0% | 30.0% | 31.2% |
| Stock-based compensation | 4.7 | 5.7 | 15.9 | 40.3 | 1.4 | 1.0 | 20.4 |
| EBITDA [+] | 95.4 | 97.4 | 127.8 | 167.4 | 182.7 | 167.9 | 134.4 |
| EBITDA growth | -2.0% | -23.8% | -23.7% | -8.3% | 8.8% | 24.9% | |
| EBITDA margin | 11.6% | 12.1% | 17.5% | 22.1% | 27.8% | 29.8% | 27.1% |
| Depreciation | 42.9 | 39.0 | 37.6 | 32.8 | 31.8 | 28.5 | 23.7 |
| EBITA | 52.6 | 58.4 | 90.2 | 134.7 | 150.9 | 139.3 | 110.7 |
| EBITA margin | 6.4% | 7.2% | 12.4% | 17.8% | 22.9% | 24.7% | 22.3% |
| Amortization of intangibles | 0.9 | 0.8 | | 1.1 | | | |
| EBIT [+] | 51.7 | 57.6 | 90.2 | 133.6 | 150.9 | 139.3 | 110.7 |
| EBIT growth | -10.3% | -36.1% | -32.5% | -11.4% | 8.3% | 25.9% | |
| EBIT margin | 6.3% | 7.2% | 12.4% | 17.7% | 22.9% | 24.7% | 22.3% |
| Non-recurring items [+] | | 2.3 | | 6.8 | | | |
| Unusual expense | | 2.3 | | | | | |
| Legal settlement | | | | 6.8 | | | |
| Interest expense | 43.6 | 32.6 | 29.3 | 35.9 | 45.4 | 44.1 | 43.3 |
| Interest expense | 43.6 | 32.6 | 29.3 | 35.9 | 45.4 | 44.1 | 43.3 |
| Other income (expense), net [+] | 0.2 | 2.7 | 6.7 | -3.4 | | | -33.9 |
| Gain (loss) on debt retirement | | | -0.5 | -4.7 | | | -33.9 |
| Pre-tax income | 8.3 | 25.4 | 67.6 | 87.5 | 105.5 | 95.3 | 33.4 |
| Income taxes | -17.8 | 2.9 | 9.5 | -0.8 | 12.4 | 12.9 | -8.2 |
| Tax rate | | 11.4% | 14.0% | | 11.7% | 13.5% | |
| Minority interest | 39.9 | 51.2 | 62.7 | 88.6 | 74.2 | 66.2 | -62.1 |
| Net income | -21.8 | -31.3 | -16.1 | -7.8 | 18.8 | 16.2 | 41.6 |
| Net margin | -2.6% | -3.9% | -2.2% | -1.0% | 2.9% | 2.9% | 8.4% |
| |
| Basic EPS [+] | ($0.68) | ($0.98) | ($0.52) | ($0.28) | $0.85 | $0.74 | $1.92 |
| Growth | -31.1% | 89.2% | 87.0% | -132.6% | 15.2% | -61.6% | |
| Diluted EPS [+] | ($0.68) | ($0.98) | ($0.52) | ($0.28) | $0.83 | $0.73 | $1.92 |
| Growth | -31.1% | 89.2% | 87.0% | -133.4% | 14.4% | -62.3% | |
| |
| Dividends per share [+] | $0.00 | $0.01 | $0.28 | $1.30 | | | |
| Growth | -85.1% | -96.3% | -78.4% | | | | |
| |
| Shares outstanding (basic) [+] | 32.3 | 32.0 | 31.1 | 28.1 | 22.2 | 21.9 | 21.7 |
| Growth | 1.0% | 2.8% | 10.5% | 26.9% | 1.0% | 1.3% | |
| Shares outstanding (diluted) [+] | 32.3 | 32.0 | 31.1 | 28.1 | 22.7 | 22.3 | 21.7 |
| Growth | 1.0% | 2.8% | 10.5% | 23.8% | 1.7% | 3.1% | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|